64 related articles for article (PubMed ID: 23130854)
1. Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease.
Barreiro-de-Acosta M; Lorenzo A; Domínguez-Muñoz JE
Rev Esp Enferm Dig; 2012 Sep; 104(9):468-72. PubMed ID: 23130854
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of and Factors Associated With Extraintestinal Manifestations and Their Remission in Inflammatory Bowel Disease: The EXTRA-Intestinal Manifestation Prospective Study From the Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif.
Guillo L; Savoye G; Amiot A; Gilletta C; Nachury M; Dib N; Bourreille A; Roblin X; Caillo L; Allez M; Picon L; Hébuterne X; Seksik P; Chupin A; Buisson A; Brixi H; Altwegg R; Simon M; Amil M; Laharie D; Bouguen G; Serrero M; Elgharabawy Y; Peyrin-Biroulet L;
Clin Transl Gastroenterol; 2023 Dec; 14(12):e00607. PubMed ID: 37523417
[TBL] [Abstract][Full Text] [Related]
3. A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease.
Falloon K; Cohen B; Ananthakrishnan AN; Barnes EL; Bhattacharya A; Colombel JF; Cross RK; Driscoll MS; Fernandez AP; Ha C; Herfarth H; Horst S; Hou J; Husni ME; Kroshinsky D; Kuhn KA; Lowder CY; Martin G; Parikh D; Sayed CJ; Schocket L; Siaton BC; Vedak P; Weisman MH; Rieder F
Aliment Pharmacol Ther; 2022 May; 55(9):1179-1191. PubMed ID: 35277863
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Association Analyses of Extraintestinal Manifestations in Inflammatory Bowel Disease.
Khrom M; Long M; Dube S; Robbins L; Botwin GJ; Yang S; Mengesha E; Li D; Naito T; Bonthala NN; Ha C; Melmed G; Rabizadeh S; Syal G; Vasiliauskas E; Ziring D; Brant SR; Cho J; Duerr RH; Rioux J; Schumm P; Silverberg M; Ananthakrishnan AN; Faubion WA; Jabri B; Lira SA; Newberry RD; Sandler RS; Xavier RJ; Kugathasan S; Hercules D; Targan SR; Sartor RB; Haritunians T; McGovern DPB
Gastroenterology; 2024 Mar; ():. PubMed ID: 38490347
[TBL] [Abstract][Full Text] [Related]
5. Impact of Treatment Response on Risk of Serious Infections in Patients With Crohn's Disease: Secondary Analysis of the PYRAMID Registry.
Ahuja D; Luo J; Qi Y; Syal G; Boland BS; Chang J; Ma C; Jairath V; Xu R; Singh S
Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1286-1294.e4. PubMed ID: 38216022
[TBL] [Abstract][Full Text] [Related]
6. The Spectrum of Extra-intestinal Manifestation of Crohn's Disease.
Jumani L; Kataria D; Ahmed MU; Shah MAA; Raja K; Shaukat F
Cureus; 2020 Feb; 12(2):e6928. PubMed ID: 32190481
[TBL] [Abstract][Full Text] [Related]
7. MIF Variant rs755622 Is Associated with Severe Crohn's Disease and Better Response to Anti-TNF Adalimumab Therapy.
Jezernik G; Gorenjak M; Potočnik U
Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833379
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab-associated Philadelphia chromosome positive acute lymphoblastic leukaemia in a patient with Crohn's disease.
Devarkonda V; Balmuri S; Akabane MACC; Akabane H
BMJ Case Rep; 2023 Oct; 16(10):. PubMed ID: 37879713
[TBL] [Abstract][Full Text] [Related]
9. [Extra-intestinal manifestations associated with Crohn's disease].
Ayada I; van Wijk MP; de Boer NK; de Hoog J; Kneepkens CMF; de Meij TJG
Ned Tijdschr Geneeskd; 2024 May; 168():. PubMed ID: 38780190
[TBL] [Abstract][Full Text] [Related]
10. Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease.
Peyrin-Biroulet L; Van Assche G; Gómez-Ulloa D; García-Álvarez L; Lara N; Black CM; Kachroo S
Clin Gastroenterol Hepatol; 2017 Jan; 15(1):25-36.e27. PubMed ID: 27392760
[TBL] [Abstract][Full Text] [Related]
11. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.
Colombel JF; Sandborn WJ; Ghosh S; Wolf DC; Panaccione R; Feagan B; Reinisch W; Robinson AM; Lazar A; Kron M; Huang B; Skup M; Thakkar RB
Am J Gastroenterol; 2014 Nov; 109(11):1771-80. PubMed ID: 25155227
[TBL] [Abstract][Full Text] [Related]
12. Incidence and Course of Joint Inflammation Associated with Inflammatory Bowel Disease in Patients Undergoing Treatment with Vedolizumab/Ustekinumab: The VEDUSTAR Study.
Gonzalez Diaz I; Gutierrez Riart M; Martin-Arranz MD; Plasencia Rodriguez C; Suarez Ferrer C; On Behalf Of Vedustar Research Team
J Clin Med; 2024 Feb; 13(4):. PubMed ID: 38398390
[TBL] [Abstract][Full Text] [Related]
13. Ophthalmological Manifestations in Inflammatory Bowel Diseases: Keep an Eye on It.
Migliorisi G; Vella G; Dal Buono A; Gabbiadini R; Busacca A; Loy L; Bezzio C; Vinciguerra P; Armuzzi A
Cells; 2024 Jan; 13(2):. PubMed ID: 38247834
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease.
Vernero M; Bezzio C; Ribaldone DG; Costa S; Scalvini D; Tribocco E; Manes G; Saibeni S
J Clin Med; 2023 Oct; 12(21):. PubMed ID: 37959304
[TBL] [Abstract][Full Text] [Related]
15. Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease.
Hanzel J; Ma C; Casteele NV; Khanna R; Jairath V; Feagan BG
Drugs; 2021 Feb; 81(3):333-347. PubMed ID: 33400241
[TBL] [Abstract][Full Text] [Related]
16. Emerging treatment options for extraintestinal manifestations in IBD.
Greuter T; Rieder F; Kucharzik T; Peyrin-Biroulet L; Schoepfer AM; Rubin DT; Vavricka SR
Gut; 2021 Apr; 70(4):796-802. PubMed ID: 32847845
[TBL] [Abstract][Full Text] [Related]
17. Assessment of extraintestinal manifestations in inflammatory bowel diseases: A systematic review and a proposed guide for clinical trials.
Guillo L; D'Amico F; Serrero M; Angioi K; Loeuille D; Costanzo A; Danese S; Peyrin-Biroulet L
United European Gastroenterol J; 2020 Nov; 8(9):1013-1030. PubMed ID: 32778004
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab and Infliximab in Crohn's disease - real life data from a national retrospective cohort study.
Preda C; Fulger L; Gheorghe L; Gheorghe C; Goldis A; Trifan A; Tantau M; Tantau A; Negreanu L; Manuc M; Cijevschi-Prelipcean C; Iacob R; Tieranu C; Meianu C; Diculescu M
Curr Health Sci J; 2016; 42(2):115-124. PubMed ID: 30568821
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn's Disease: A Pooled Analysis of 11 Clinical Studies.
Louis EJ; Reinisch W; Schwartz DA; Löfberg R; Robinson AM; Berg S; Wang AW; Maa JF; Huang B; Pappalardo B
Adv Ther; 2018 Apr; 35(4):563-576. PubMed ID: 29516410
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
